Back to search

Article

M184V: The Major Determinant of Cooperative ISL Resistance When in Combination with Multiple TAM2 Mutations in HIV-1 Subtype C

2026-08-27

Abstract excerpt

Islatravir is a novel nucleoside reverse transcriptase translocation inhibitor under clinical investigation for the treatment of HIV-1 infection. While we previously documented high-level phenotypic resistance to islatravir (ISL) in HIV-1 subtype C variants harboring combinations of type 2 thymidine analogue mutations (TAM2) along with the M184V resistance-associated mutation, the primary contributor to the observ...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
48e8c6ae-f9af-5b58-b9b4-6bf7e055efbd
DOI
10.20944/preprints202608.2036.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
M184V: The Major Determinant of Cooperative ISL Resistance When in Combination with Multiple TAM2 Mutations in HIV-1 Subtype CDOI 10.20944/preprints202608.2036.v1
Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir.Semantic proximity
Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).Semantic proximity
Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.Semantic proximity
HIV-1 resistance to islatravir/tenofovir combination therapy in wild-type or NRTI resistant strains of diverse HIV-1 subtypesSemantic proximity
HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes.Semantic proximity
No antagonism or cross-resistance and a high barrier to the emergence of resistance in vitro for the combination of islatravir and lenacapavir.Semantic proximity
Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy.Semantic proximity
Kinetic Investigation of Resistance to Islatravir Conferred by Mutations in HIV-1 Reverse Transcriptase.Semantic proximity
Kinetic Insights into the Enhanced Antiviral Activity of Islatravir against Doravirine Resistance-Associated Substitution Mutations in HIV-1 Reverse Transcriptase.Semantic proximity
The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir.Semantic proximity
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro.Semantic proximity
Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.Semantic proximity
Select a neighboring publication to make it the new centre.